Indegene Shares Rise on Buy Ratings from Axis Direct and Motilal Oswal
Indegene's share price rose nearly 5% to a 52-week high following buy recommendations from Axis Direct and Motilal Oswal. Axis highlighted Indegene's strong AI-driven life sciences expertise and diversified growth pipeline, while Motilal Oswal emphasized the company's role in streamlining global pharma content and regulatory processes. Both firms see potential for further gains, with Motilal Oswal setting a target price of Rs 708 based on FY28 earnings projections.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (75/100). Lens Score 32/100.
Outlets measured: mint, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (75–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 25 Sept, 06:14 am. Other outlets followed.